Health Canada, the Canadian version of the FDA, said it is taking a long look at the association between the diabetes drug Actos (pioglitazone) and bladder cancer. France and Germany have already ceased Actos sales after more information is coming to light about the connection between Actos and bladder cancer.
The Health Canada press release said:
Health Canada has been closely monitoring this potential risk, and has been reviewing all relevant studies on an ongoing basis. We are taking these studies, including their strengths and limitations, into account as we continue to monitor pioglitazone safety.
- Actos recall/withdraw speculation by us